Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VH 4011499

Next Previous
X
Search
Drug Profile

VH 4011499

Alternative Names: GSK-4011499; VH-4011499; VH-4011499-A; VH-499

Latest Information Update: 16 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ViiV Healthcare
  • Class Antiretrovirals
  • Mechanism of Action Capsid protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 09 Dec 2024 ViiV Healthcare plans a phase I trial (In volunteers) (SC) (IM) in December 2024 in the US (NCT06724640)
  • 24 Jun 2024 ViiV Healthcare completes the phase II CINNAMON trial in HIV-1 infections (Treatment-naive) in USA, Argentina, Canada, France, Germany, Italy, Mexico, Spain and UK(PO) (NCT06039579) (EudraCT2023-505350-18-00)
  • 17 Apr 2024 ViiV Healthcare initiates enrolment in a phase I trial for HIV infections (In volunteers) in USA (PO, Tablet) (NCT06368986)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top